SS-31 Elamipretide Peptide: Research Guide and Where to Buy

Written by the Core Power Peptides Research Team — biochemists and laboratory specialists compiling and verifying peptide research data. Learn about our quality standards →

Most antioxidant strategies work downstream — scavenging reactive oxygen species after mitochondria have already produced them. SS-31 takes a structurally different approach: it concentrates in the inner mitochondrial membrane and binds cardiolipin directly, addressing oxidative stress at its point of origin. That distinction is a large part of why the compound has become one of the most-cited mitochondrial-targeted peptides in the geroscience literature.

SS-31 (Elamipretide): Structure and Cardiolipin Affinity

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide developed by Stealth BioTherapeutics that selectively concentrates in the inner mitochondrial membrane. Its sequence — D-Arg-Dmt-Lys-Phe-NH2 — includes a dimethyltyrosine residue that confers high affinity for cardiolipin, the signature phospholipid of the inner mitochondrial membrane and a critical structural component of the electron transport chain (ETC).

Monthly search interest in “SS-31 for sale” and related terms has risen sharply since 2023, reflecting growing research demand in aging, cardiovascular, and neurodegenerative disease study. As mitochondrial dysfunction has moved to the center of geroscience research, SS-31 has become one of the most-cited mitochondrial-targeted peptides in the published literature.

Mechanism of Action

SS-31 exerts its effects through direct interaction with cardiolipin in the inner mitochondrial membrane:

• Cardiolipin Stabilization: Binds cardiolipin and prevents its oxidation by cytochrome c, preserving membrane structure
• ETC Complex I–IV Optimization: Restores electron transfer efficiency across complexes I, III, and IV
• ROS Suppression: Reduces mitochondrial reactive oxygen species production at the source
• ATP Production: Increases ATP synthesis by improving proton gradient maintenance
• Cristae Architecture: Preserves inner membrane cristae structure essential for energy coupling
• Mitochondrial Dynamics: Supports balanced fusion and fission by preventing cardiolipin redistribution

Unlike antioxidants that act downstream after ROS are produced, SS-31 targets the origin point of mitochondrial oxidative stress, making it particularly valuable for research into chronic mitochondrial dysfunction states.

Preclinical and Clinical Research Data

Cardiac Research

SS-31 has generated compelling data in cardiac ischemia-reperfusion (I/R) injury models:

• Multiple rodent studies demonstrate 40–60% reduction in infarct size when administered before or at reperfusion
• Preserved left ventricular function and reduced cardiomyocyte apoptosis in I/R models
• Phase 2 EMBRACE-STEMI trial (2015) showed trends toward improved microvascular function in STEMI patients, though primary endpoint was not met
• Phase 2 PROGRESS-HF trial investigated SS-31 (elamipretide) in HFrEF (heart failure with reduced ejection fraction), showing improvements in exercise tolerance and quality of life markers

Aging and Skeletal Muscle

A landmark 2021 Nature Aging study demonstrated that systemic SS-31 administration in aged mice:

• Reversed age-related declines in mitochondrial ATP production in skeletal muscle
• Improved muscle fiber morphology and contractile function
• Reduced markers of mitochondrial oxidative stress and inflammation
• These effects persisted beyond the treatment period, suggesting durable mechanistic changes

Renal Research

SS-31 has also been investigated in acute kidney injury (AKI) models:

• Reduced renal tubular cell apoptosis in cisplatin-induced AKI models
• Improved glomerular filtration rate markers and renal mitochondrial membrane potential
• Attenuated inflammatory cytokine production in ischemic renal injury models

Neurodegeneration Models

• Reduced amyloid-β-induced mitochondrial dysfunction in Alzheimer’s cell models
• Preserved dopaminergic neuron mitochondrial function in MPTP-induced Parkinson’s models
• Improved cognitive performance markers in aged rodent models

Dosage Reference for Research

For research reference only. Not dosing guidance for human use.

SS-31 vs. MitoQ — Research Comparison

Safety and Tolerability

SS-31 has demonstrated a favorable safety profile across preclinical species and in Phase 2 human trials:

• No significant organ toxicity at therapeutic doses in rodent and primate studies
• Most common adverse events in human trials: mild injection site reactions
• No dose-limiting toxicity observed in completed Phase 2 programs
• Peptide does not cross the blood-brain barrier in significant quantities (relevant for CNS research design)

Where to Buy SS-31 for Research

When sourcing SS-31 for laboratory use, quality criteria to prioritize:

• HPLC purity ≥99% with certificate of analysis
• Mass spectrometry (LCMS) identity confirmation per batch
• Sterility testing and endotoxin documentation
• Lyophilized format for long-term stability at −20°C

HPLC Verified

SS-31 (Elamipretide) 10mg

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$150

Buy Now

HPLC Verified

SS-31 (Elamipretide) 50mg

Purity: 99%+ HPLC

Format: Bulk Lyophilized

Testing: Third-Party COA

$600

Buy Now

Frequently Asked Questions

Why does cardiolipin binding matter mechanistically?

Cardiolipin is the signature phospholipid of the inner mitochondrial membrane and a structural requirement for efficient electron transport chain function. When cytochrome c oxidizes cardiolipin, cristae architecture degrades and electron transfer becomes leaky — producing ROS. SS-31 binds cardiolipin and prevents that oxidation, which is why its effects register upstream rather than downstream.

Does SS-31 cross the blood-brain barrier?

Not in significant quantities. This is a meaningful constraint for CNS research design — studies reporting neuroprotective effects in Alzheimer’s and Parkinson’s models generally rely on cell culture systems or account for limited CNS penetration in their protocol design.

What is the current clinical research status?

SS-31 has completed Phase 2 programs. The EMBRACE-STEMI trial in 2015 showed trends toward improved microvascular function in STEMI patients without meeting its primary endpoint; PROGRESS-HF, in heart failure with reduced ejection fraction, showed improvements in exercise tolerance and quality of life markers. No dose-limiting toxicity was observed across completed Phase 2 work.

Everything above is summarized for scientific reference only. SS-31 has not been approved for human use; material supplied by Core Power Peptides is restricted to in vitro and laboratory research, and researchers remain responsible for compliance with applicable local regulations.